Research Topics
Genomes and Genes
| Charles G DrakeSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Current status of immunological approaches for the treatment of prostate cancerCharles G Drake
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Curr Opin Urol 22:197-202. 2012....- Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigenCharles G Drake
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Cancer Cell 7:239-49. 2005..These results suggest that immunotherapy for prostate cancer may be most efficacious when administered after androgen ablation... - Immunotherapy for prostate cancer: an emerging treatment modalityCharles G Drake
Departments of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street CRB I 410, Baltimore, MD 21231, USA
Urol Clin North Am 37:121-9, Table of Contents. 2010.... - Basic overview of current immunotherapy approaches in urologic malignancyCharles G Drake
Oncology, Immunology, and Urology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
Urol Oncol 24:413-8. 2006..Various compensatory mechanisms which serve to down-regulate an antitumor response are also examined... - Update: immunological strategies for prostate cancerCharles G Drake
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 410, Baltimore, MD, 21231, USA
Curr Urol Rep 11:202-7. 2010..Enthusiasm for prostate cancer immunotherapy is founded upon its potential to mediate targeted, specific, tumor cell destruction without significant systemic toxicity; however, this has yet to be fully realized in the clinical arena... - Prostate cancer as a model for tumour immunotherapyCharles G Drake
Johns Hopkins Kimmel Cancer Center, 1650 Orleans Street CRB 410, Baltimore, Maryland 21231, USA
Nat Rev Immunol 10:580-93. 2010..Although this Review focuses on immunotherapy for prostate cancer, the principles discussed are applicable to many tumour types, and the approaches discussed are highlighted in that context... - Update on prostate cancer vaccinesCharles G Drake
Johns Hopkins Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
Cancer J 17:294-9. 2011..clinicaltrials.gov... - Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer modelSatoshi Wada
Department of Oncology, James Buchanan Brady Urological Institute, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Cancer Res 69:4309-18. 2009..Taken together, these data clarify the dose, timing, and mechanism of action by which immunomodulatory cyclophosphamide can be translated to a clinical setting in a combinatorial cancer treatment strategy... - Tc17 CD8 T cells: functional plasticity and subset diversityHung Rong Yen
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Immunol 183:7161-8. 2009..Tc17 also accumulated to a greater extent than did Tc1 cells, suggesting that adoptive transfer of CD8 T cells cultured in Tc17 conditions may have therapeutic potential for diseases in which IFN-gamma-producing cells are desired... - Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cellsJoseph F Grosso
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Immunol 182:6659-69. 2009.... - Radiotherapy augments the immune response to prostate cancer in a time-dependent mannerTimothy J Harris
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Prostate 68:1319-29. 2008..To address this, we utilized a well-established, autochthonous murine model of prostate cancer to test whether RT could augment (or diminish) the CD4 T cell response to a tumor vaccine... - Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cellsDerese Getnet
Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
J Immunol 182:4675-85. 2009..Interestingly, this Treg skewing was a property of even early-stage tumors, suggesting Treg induction as an important tolerance mechanism during tumor development... - A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cellsDerese Getnet
Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
Mol Immunol 47:1595-600. 2010..Taken together, these data suggest that Helios may play an important role in regulatory T cell function and support the concept that Helios may be a novel target to manipulate Treg activity in a clinical setting... - LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systemsJoseph F Grosso
Sidney Kimmel Comprehensive Cancer Center and Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
J Clin Invest 117:3383-92. 2007..Taken together, these data demonstrate a direct role for LAG-3 on CD8+ T cells and suggest that LAG-3 blockade may be a potential cancer treatment... - A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cellsPaul E Zarek
Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Blood 111:251-9. 2008..Overall, our findings demonstrate that extracellular adenosine stimulates the A(2A)R to promote long-term T-cell anergy and the generation of adaptive regulatory T cells... - Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewingKaren Sandell Sfanos
Department of Urology, James Buchanan Brady Urological Institute, MD, USA
Clin Cancer Res 14:3254-61. 2008..Little is known about the phenotype of these cells, despite accumulating evidence suggesting a potential role for chronic inflammation in the etiology of prostate cancer... - Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic modelTullia C Bruno
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
Prostate 72:514-22. 2012..This may occur via deletion of tumor-specific T cells, through acquisition of an anergic phenotype, or via active suppression mediated by another population of cells... - Role of LAG-3 in regulatory T cellsChing Tai Huang
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
Immunity 21:503-13. 2004..We propose that LAG-3 marks regulatory T cell populations and contributes to their suppressor activity... - Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+Karen S Sfanos
Department of Pathology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231, USA
Prostate 69:1694-703. 2009.... - Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccinesGang Zhou
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Blood 107:628-36. 2006.... - Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunityTimothy J Harris
Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
J Immunol 179:4313-7. 2007..Thus, STAT3 is a candidate target for T(H)17-dependent autoimmune disease immunotherapy that could selectively inhibit pathogenic immune pathways... - Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cellsFan Pan
Immunology and Hematopoiesis Division, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Science 325:1142-6. 2009..Silencing of Eos in Tregs abrogates their ability to suppress immune responses and endows them with partial effector function, thus demonstrating the critical role that Eos plays in Treg programming... - Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancerDaniel J Zabransky
Johns Hopkins Kimmel Cancer Center, Johns Hopkins University, Baltimore, Maryland
Prostate 72:487-98. 2012.... - Current status of immunological therapies for prostate cancerEmmanuel S Antonarakis
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
Curr Opin Urol 20:241-6. 2010..This review will discuss the most promising immune-directed strategies in development for prostate cancer, outlining interventions that mitigate tumor-induced tolerance and highlighting several combination immunotherapy approaches... - STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine modelVedran Radojcic
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Immunol 184:764-74. 2010.... - Current immunotherapeutic strategies in prostate cancerJoseph F Grosso
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street, CRB 452, Baltimore, MD 21231, USA
Surg Oncol Clin N Am 16:861-71, x. 2007..Most likely, successful immunotherapy will eventually require either the combination of multiple immunologic approaches or the combination of immunologic approaches with conventional therapy... - Phenotypic and functional properties of Helios+ regulatory T cellsDaniel J Zabransky
Department of Oncology, Johns Hopkins University, Baltimore, Maryland, United States of America
PLoS ONE 7:e34547. 2012..Taken together, these data show that Helios(+) Treg represent a functional subset with associated CD103 and GITR expression... - Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJulie R Brahmer
Johns Hopkins University School of Medicine, and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
J Clin Oncol 28:3167-75. 2010..This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates... - CD4+ T cells pass through an effector phase during the process of in vivo tolerance inductionChing-Tai Huang
Oncology Center and Division of Comparative Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
J Immunol 170:3945-53. 2003..They also suggest that autoimmune pathology can result during the natural process of tolerance induction rather than requiring that tolerance be broken... - Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablationMoshe Yair Levy
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Pharmacol Exp Ther 330:596-601. 2009..The combination of tumor cryoablation and Cy induces potent, systemic antitumor immunity in animals with established metastatic disease... - Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cellsMonica V Goldberg
Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
Blood 110:186-92. 2007..These findings demonstrate that, in addition to modulating effector functions in the periphery, B7-H1:PD-1 interactions regulate early T-cell-fate decisions... - Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studiesElizabeth A Platz
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Rm E6132, Baltimore, MD 21205, USA
Cancer Causes Control 21:847-51. 2010..The authors estimated the size of this source of variability and consequent attenuation of the relative risk (RR)... - Bacteriolytic therapy can generate a potent immune response against experimental tumorsNishant Agrawal
Howard Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
Proc Natl Acad Sci U S A 101:15172-7. 2004..Similar effects were observed in rabbits with intrahepatic tumors. It was particularly notable that the induced immune response, when combined with the bacteriolytic effects of C. novyi-NT, could eradicate large established tumors... - Inflammation in prostate carcinogenesisAngelo M De Marzo
Johns Hopkins University School of Medicine, Department of Pathology, Baltimore, MD, USA
Nat Rev Cancer 7:256-69. 2007.... - LAG-3 in Cancer ImmunotherapyMonica V Goldberg
Johns Hopkins Kimmel Cancer Center, 1650 Orleans Street CRB 423, Baltimore, MD 21231, USA
Curr Top Microbiol Immunol 344:269-78. 2011..In this review, we will first discuss the basic structural and functional biology of LAG-3, followed by a review of preclinical and clinical data pertinent to a role for LAG-3 in cancer immunotherapy... - Immunotherapy for metastatic prostate cancerCharles G Drake
Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
Urol Oncol 26:438-44. 2008..The relative advantages and disadvantages of current approaches will be noted, and ongoing clinical trials will be highlighted... - Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE IIMing Hsi Wang
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe Street, Baltimore, MD 21205, USA
Prostate 69:874-85. 2009..Chronic intra-prostatic inflammation and obesity are thought to influence prostate carcinogenesis. Thus, variants in genes in these pathways could be associated with prostate cancer risk... - Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical dataTakeshi Azuma
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
PLoS Med 6:e1000166. 2009..Here we sought to investigate whether B7-H4, a cell surface inhibitory molecule of the B7-CD28 signaling pathway, may play a role in the pathogenesis of RA... - Ipilimumab: an anti-CTLA-4 antibody for metastatic melanomaEvan J Lipson
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
Clin Cancer Res 17:6958-62. 2011..Here, we review the mechanism of action, preclinical data, and multiple clinical trials that led to FDA approval of ipilimumab for metastatic melanoma... - Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cellsIvan V Litvinov
Chemical Therapeutics Program, Division of Immunology and Hematopoiesis, The Sidney Kimmel Comprehensive Cancer Center, Department of Pathology, and The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Proc Natl Acad Sci U S A 103:15085-90. 2006..Thus, AS prostate cancer cells do not express AR protein during mitosis, either in vitro or in vivo, consistent with AR functioning as a licensing factor for DNA replication in AS prostate cancer cells... - Epithelial architectural destruction is necessary for bone marrow derived cell contribution to regenerating prostate epitheliumGanesh S Palapattu
Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
J Urol 176:813-8. 2006..CONCLUSIONS: These findings are consistent with a requirement for inflammation associated architectural destruction for the bone marrow derived cell contribution to the regeneration of prostate epithelium... - Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunitySuzanne L Topalian
Department of Surgery, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
Curr Opin Immunol 24:207-12. 2012..Encouraging early clinical results using blocking agents against components of the PD-1 pathway have validated its importance as a target for cancer immunotherapy... - Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyEmmanuel S Antonarakis
Departments of Oncology, Urology and Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Curr Opin Oncol 24:258-65. 2012..In this article, we will summarize recent clinical data on several additional immune-directed strategies, some of which have now entered phase 3 trials... - Cutting Edge: TCR-induced NAB2 enhances T cell function by coactivating IL-2 transcriptionSamuel Collins
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Immunol 177:8301-5. 2006..Indeed, chromatin immunoprecipitation analysis reveals that NAB2 is recruited to the Egr-1 binding site of the IL-2 promoter. Taken together, our findings identify NAB2 as a novel coactivator of T cell function... - Tumor immunology--towards a paradigm of reciprocal researchCharles G Drake
Johns Hopkins Department of Medical Oncology, Baltimore, MD 21231, USA
Semin Cancer Biol 12:73-80. 2002..The results of early clinical trials illustrate these points and underscore the critical importance of an interactive dialog between laboratory and clinical research efforts... - Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector functionAmy D H Doody
Center for Immunotherapy of Cancer and Infectious Diseases, University of Connecticut Health Center, Farmington, CT 06030, USA
J Immunol 172:6087-92. 2004..Taken together, these data suggest that gp96 is an inflammatory mediator that selectively primes CD8 cell effector function... - B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cellsMichelle A Hurchla
Department of Pathology, Center for Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
J Immunol 174:3377-85. 2005..These results clarify discrepancies regarding BTLA expression, suggest that structural and expression polymorphisms be considered when analyzing BTLA in various murine backgrounds, and indicate a possible role in anergic CD4+ T cells... - Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapyEvan T Keller
Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
Cancer Res 67:9613-5. 2007
Research Grants
- Regulation of the Immune Response to Prostate CancerCharles Drake; Fiscal Year: 2007..Finally, the research and training program outlined in this proposal makes full use of the collaborative and educational opportunities offered by the Johns Hopkins Oncology Center, where this work will be performed. ..
- Analysis of Lag-3 in Regulatory T Cell Function and Immune SupressionCharles Drake; Fiscal Year: 2009..The overall goal of these studies is to understand how LAG-3 works, and then to use this information to target LAG-3 in an effort to improve immune treatments for cancer patients. ..
- Analysis of Lag-3 in Regulatory T Cell Function and Immune SupressionCharles G Drake; Fiscal Year: 2010..The overall goal of these studies is to understand how LAG-3 works, and then to use this information to target LAG-3 in an effort to improve immune treatments for cancer patients. ..